Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kontigo Care ABFRA:3KT +4.92%25 EBITDA Margin % is 23.80% as of Mar. 2026, which is 120% above its 10-year median of 10.83. GuruFocus rates FRA:3KT with a GF Score™ of 25/100 and a GF Value™ of €0.10. The stock has 1 warning sign investors should review. Among 662 Healthcare Providers & Services companies, Kontigo Care AB ranks better than 62.24% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Kontigo Care AB's EBITDA for the
three
months ended in Mar. 2026 was €0.16 Mil. Kontigo Care AB's Revenue for the
three
months ended in Mar. 2026 was €0.69 Mil. Therefore, Kontigo Care AB's EBITDA margin for the quarter that ended in Mar. 2026 was 23.80%.
Kontigo Care AB (FRA:3KT) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Kontigo Care AB EBITDA Margin % Related Terms
Kontigo Care AB EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Kontigo Care AB's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:3KT vs VEEV, BTSG, TEM: EBITDA Margin % Comparison
For the Health Information Services subindustry, Kontigo Care AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kontigo Care AB EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Kontigo Care AB's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Kontigo Care AB's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kontigo Care AB (FRA:3KT) has a EBITDA Margin % of 23.80% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kontigo Care AB and its competitors. This is 120% above median its historical median of 10.83. According to the industry distribution chart, Kontigo Care AB ranks #250 out of 662 companies in the Healthcare Providers & Services industry, placing it in the top 37.8%.
Is Kontigo Care AB's EBITDA Margin % too high?
Kontigo Care AB's current EBITDA Margin % of 23.80% is 120% above median its 10-year median of 10.83. The Healthcare Providers & Services industry median EBITDA Margin % is 10.25. Kontigo Care AB's value of 23.80% is 132.2% above this industry median. Based on the distribution chart, Kontigo Care AB ranks #250 out of 662 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Kontigo Care AB has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Kontigo Care AB's EBITDA Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Kontigo Care AB ranks #250 out of 662 companies for EBITDA Margin %. This puts Kontigo Care AB in the upper half of its industry. The industry median EBITDA Margin % is 10.25. Kontigo Care AB's value of 23.80% is 132.2% above this benchmark. While the company's 10-year median is 10.83 vs. the industry median of 10.25, Kontigo Care AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.25, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kontigo Care AB's current EBITDA Margin % of 23.80% is 132.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kontigo Care AB and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kontigo Care AB's current EBITDA Margin % is 23.80%, which is 120% above median its own 10-year median of 10.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kontigo Care AB stock overvalued right now?
Kontigo Care AB (FRA:3KT) has a current EBITDA Margin % of 23.80%. The stock's GF Value™ is €0.10, compared to a current price of €0.09 — trading 10.4% below its estimated fair value. The current EBITDA Margin % is 23.80%, which is 120% above median its 10-year median of 10.83 and 132.2% above the Healthcare Providers & Services industry median of 10.25. Kontigo Care AB's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Kontigo Care AB (FRA:3KT), the current EBITDA Margin % is 23.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kontigo Care AB (FRA:3KT) Overvalued in 2026?
Based on GuruFocus' analysis, Kontigo Care AB stock appears to be undervalued.
The current stock price of €0.09 is trading 10.4% below its estimated GF Value™ of €0.10.
Key valuation signals for FRA:3KT:
EBITDA Margin %: 23.80% (120% above median its 10-year median of 10.83)
GF Value™: €0.10 vs. price of €0.09 (10.4% below fair value)
Industry Position: 132.2% above the Healthcare Providers & Services median (#250 of 662)
No single metric tells the full story. See the FRA:3KT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kontigo Care AB is a Sweden based company involved in offering a cloud-based platform with artificial intelligence (AI) and predictive capabilities. Its Kontigo Care platform has predictive capabilities, which means that a relapse can be identified early and, in some cases, completely prevented.
25GF Score
Get the complete analysis for FRA:3KT
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3KT has been successfully added to your 
